Curing Autoinflammation
Zistimmune is creating first-in-class therapies to stop inflammation in chronic diseases.
Our first patented antibody targets human resistin at the site of pathology, halting runaway inflammation and restoring healthy immune function.
Initial indications include pulmonary hypertension and associated cardiac hypertrophy and failure, an orphan disease which our founder’s laboratory has extensively studied and for which no cure has yet been discovered.
Our pipeline and intellectual property include, but are not limited to, pulmonary fibrosis, chronic obstructive pulmonary disease (COPD), viral lung disease, atherosclerosis, scleroderma, asthma, and wound healing. Rheumatoid arthritis and inflammatory bowel disease are further targets.
While we build our team, pipeline and website, our founder and Chief Science Officer, Roger A. Johns, M.D., Ph.D. welcomes your interest.
Contact him at
